Observational studyCancer medicine2025
Impact of Hypertension on Cancer Stage at Diagnosis Among French Women: The E3N Prospective Cohort.
Observational study in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03285230 (The French E3N Prospective Cohort Study), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The French E3N Prospective Cohort Study (Etude Epidémiologique auprès de Femmes de la Mutuelle Générale de l'Education Nationale)
Who cites it
2 citing papers in PubMed.
- Cancer and Hypertension: Shared Mechanisms, Treatment Interactions, and Clinical Management.Cancer medicine · 2026Review
- Impact of Hypertension on Cancer Stage at Diagnosis Among French Women: The E3N Prospective Cohort.Cancer medicine · 2025Observational
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
Abstract
introductionHypertension may delay the detection of metastatic cancers. We investigated the association between incident hypertension and the risk of metastatic onset among female cancer patients. We studied notably the role of anti-hypertensive treatment and the time between hypertension onset and cancer diagnosis in this association.
methodsE3N is a French prospective population-based cohort that recruited 98,995 women in 1990. A total of 7844 incident invasive cancers were examined. We used multivariate logistic regression models to calculate odds ratios (OR) and their 95% confidence intervals (CI). We also used restricted cubic splines to evaluate the nonlinear dose-response associations between hypertension duration and the risk of metastatic onset (vs. localised stage).
resultsA total of 1994 cases (25%) of incident hypertension occurred before cancer diagnosis. Compared to non-hypertensive patients, those with untreated hypertension presented more frequently with metastatic cancer among patients who regularly underwent cancer screening (OR = 1.69, 95% CI = 1.11-2.58). This association was inverse among those who did not screen regularly (OR = 0.53, 95 CI = 0.29-0.98). Treated hypertensive patients had significantly greater odds of metastatic presentation for thyroid (OR = 2.45, 95% CI = 1.01-5.91) and lower odds for lung (OR = 0.17, 95% CI = 0.06-0.52) cancer. A significant inverse U-shaped association with time from hypertension onset (p = 0.01) was observed.
conclusionIn this study, hypertension was associated with metastatic cancer presentation, but cancer screening determined the direction of the association. Time from hypertension onset was inversely associated with metastatic lung cancer, with a significant nonlinear dose-response relationship. Our findings call for further research in this area to investigate the underlying mechanisms.
trial registrationclinicaltrials.gov identifier: NCT03285230.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.